These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18189332)

  • 1. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
    Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
    J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
    Linderoth J; Ehinger M; Akerman M; Cavallin-Ståhl E; Enblad G; Erlanson M; Jerkeman M
    Eur J Haematol; 2007 Aug; 79(2):146-9. PubMed ID: 17635238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
    Walker SR; Nelson EA; Frank DA
    Oncogene; 2007 Jan; 26(2):224-33. PubMed ID: 16819511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
    Basso K; Dalla-Favera R
    Adv Immunol; 2010; 105():193-210. PubMed ID: 20510734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma.
    Wang HY; Bossler AD; Schaffer A; Tomczak E; DiPatri D; Frank DM; Nowell PC; Bagg A
    Cancer Genet Cytogenet; 2007 Jan; 172(1):45-53. PubMed ID: 17175379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDCD2, a protein whose expression is repressed by BCL6, induces apoptosis in human cells by activation of the caspase cascade.
    Baron BW; Hyjek E; Gladstone B; Thirman MJ; Baron JM
    Blood Cells Mol Dis; 2010 Aug; 45(2):169-75. PubMed ID: 20605493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
    Rodig SJ; Savage KJ; LaCasce AS; Weng AP; Harris NL; Shipp MA; Hsi ED; Gascoyne RD; Kutok JL
    Am J Surg Pathol; 2007 Jan; 31(1):106-12. PubMed ID: 17197926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Sierra J; Prat J
    Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis.
    Jardin F; Sahota SS
    Hematology; 2005 Apr; 10(2):115-29. PubMed ID: 16019457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations.
    Keller CE; Nandula S; Fisher J; Subramaniyam S; Vakiani E; Savage DG; Murty VV; Alobeid B; Bhagat G
    Am J Clin Pathol; 2008 Aug; 130(2):193-201. PubMed ID: 18628087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
    Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
    Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.